New drug combo aims to outperform keytruda in head and neck cancer
NCT ID NCT07264075
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial is testing two new drug combinations—ivonescimab alone or with ligufalimab—against the standard treatment pembrolizumab (Keytruda) for people with advanced head and neck cancer that has come back or spread. The study will enroll about 780 participants to see if the new treatments help them live longer. The goal is to find a better first-line option for this type of cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (with or without ligufalimab) compared to pembrolizumab
- What this could lead to
- If successful, this could offer a new first-line treatment option for recurrent or metastatic head and neck cancer, potentially improving survival.
- What could go wrong
- This is an early-stage Phase 3 trial, so results are not guaranteed. The experimental drugs may not outperform pembrolizumab, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA HEAD AND NECK CANCER (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Guillaume Le Conquerant
RECRUITINGLe Havre, 76600, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study: can early palliative care help head and neck cancer patients suffer less?
- AI reads social media posts to spot suicide risk in skin cancer patients
- Could a 3-Week radiation course replace 6 weeks for head and neck cancer?
- Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
- New test could predict immunotherapy success from live tumor samples
- Blood test may spot head and neck Cancer's return